Home › Encyclopedia › CJC-1295: Research Status and Clinical Trial Data
Research / Unapproved

CJC-1295: Research Status and Clinical Trial Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC165H269N47O46
Molecular weight3647.2 g/mol
Registered trials1
PubChem CID91971820

Key takeaways

  • CJC-1295 has no FDA-approved label and is classified as an unapproved research compound.
  • It is a large synthetic peptide with the molecular formula C165H269N47O46 and a molecular weight of about 3,647 g/mol.
  • One trial has been registered in the clinicaltrials database.
  • The available trial involved HIV patients with visceral obesity and was terminated before completion.

What CJC-1295 is

CJC-1295 is a synthetic peptide compound identified in chemical databases under PubChem CID 91971820. It has not been reviewed or approved by any drug regulatory authority, and no official prescribing label exists for it. Because it lacks an approved label, there is no regulatory description of its mechanism, indications, or safety profile available for this monograph.

Trial footprint

Registry data show a single clinical trial involving CJC-1295. That study, "A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity" (NCT00267527), examined the compound in patients with HIV-associated visceral obesity. The trial's status is listed as terminated, meaning it ended before reaching its planned conclusion. No outcome data or additional trials are available in the current dataset.

FAQ

Is CJC-1295 FDA approved?
No. CJC-1295 has no FDA-approved label and is considered an unapproved research compound. No official prescribing information or approved indication exists for it.
What is CJC-1295 chemically?
CJC-1295 is a synthetic peptide with the molecular formula C165H269N47O46 and a molecular weight of approximately 3,647 g/mol. It is cataloged in PubChem under CID 91971820.
Has CJC-1295 been studied in clinical trials?
One clinical trial involving CJC-1295 is registered in public trial databases. It examined the compound in HIV patients with visceral obesity, but the study was terminated before completion.
What was the outcome of the CJC-1295 clinical trial?
The registered trial, NCT00267527, is listed with a terminated status, meaning it stopped before reaching its planned endpoints. No published outcome data from this trial is included in the available records.
Are there known side effects of CJC-1295?
No adverse event report data is currently available for CJC-1295 in this dataset. Because it lacks an approved label, there is no official safety information to summarize.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-08-03